AR046163A1 - Combinaciones de farmacos para el tratamiento de neoplasmas - Google Patents
Combinaciones de farmacos para el tratamiento de neoplasmasInfo
- Publication number
- AR046163A1 AR046163A1 ARP040103378A ARP040103378A AR046163A1 AR 046163 A1 AR046163 A1 AR 046163A1 AR P040103378 A ARP040103378 A AR P040103378A AR P040103378 A ARP040103378 A AR P040103378A AR 046163 A1 AR046163 A1 AR 046163A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- patient
- group
- compound
- administering
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 239000000890 drug combination Substances 0.000 title 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 3
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- -1 bis-benzimidazole compound Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical class C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 abstract 1
- 108010051357 endoexonuclease Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Método para tratar a un paciente que tiene cáncer u otro neoplasma, administrando al paciente clorpormazina o un análogo de clorpromazina y un agente antiproliferativo de manera simultánea o dentro de los 14 días uno del otro en cantidades suficientes para tratar al paciente, composición y kit. Reivindicación 1: Un método para tratar a un paciente con diagnóstico o con riesgo de desarrollar un neoplasma, que comprende la administración a dicho paciente de: a) un compuesto que tiene la fórmula (1), o una de sus sales farmacéuticamente aceptables, en donde R2 es CF3, halógeno, OCH3, COCH3, CN, OCF3, COCH2CH3, CO(CH2)2CH3 o SCH2CH3; R9 se selecciona del resto de grupo de fórmula (2), o R9 tiene la fórmula (3), en donde n es 0 o 1, Z es NR35R36 u OR37; cada uno de R32, R33, R34, R35, R36 y R37 es, de modo independiente, H, alquilo C1-7, alquenilo C2-7, alquinilo C2-7, heterociclilo C2-6, arilo C6-12, alcarilo C7-14, alkheterociclilo C3-10, acilo o heteroalquilo C1-7; o cualquiera de R33, R34, R35, R36 y R37 puede tomarse opcionalmente junto con el átomo de carbono interviniente o átomos de O, S o N no vecinales para formar uno o varios anillos de cinco a siete miembros, opcionalmente sustituidos con H, halógeno, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, heterociclilo C2-6, arilo C6-12, alcarilo C7-14, alkheterociclilo C3-10, acilo o heteroalquilo C1-7; cada uno de R1, R3, R4, R5, R6, R7 y R8 es, de modo independiente, H, OH, F, OCF3 u OCH3; y W es NO, o un grupo de fórmulas (4), b) un agente antiproliferativo del grupo A, en donde dicho compuesto de la fórmula (1) y dicho agente antiproliferativo del grupo A se administran simultáneamente o dentro de los 14 días uno del otro, en cantidades que juntas son suficientes para inhibir el crecimiento de dicho neoplasma y con la condición de que dicho método no incluya la administración de un compuesto de bis-bencimidazol, un inhibidor de endo-exonucleasa, un inhibidor de PRL fosfatasa o un inhibidor de PTP1B dentro de los 20 días de haber administrado dicho compuesto de la fórmula (1).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50431003P | 2003-09-18 | 2003-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046163A1 true AR046163A1 (es) | 2005-11-30 |
Family
ID=34375474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103378A AR046163A1 (es) | 2003-09-18 | 2004-09-20 | Combinaciones de farmacos para el tratamiento de neoplasmas |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20050137185A1 (es) |
| EP (1) | EP1670477A2 (es) |
| JP (1) | JP2007505914A (es) |
| KR (1) | KR20070012618A (es) |
| CN (1) | CN1878556A (es) |
| AR (1) | AR046163A1 (es) |
| AU (1) | AU2004273910A1 (es) |
| BR (1) | BRPI0414568A (es) |
| CA (1) | CA2538570A1 (es) |
| IL (1) | IL174232A0 (es) |
| IS (1) | IS8398A (es) |
| MX (1) | MXPA06003066A (es) |
| NO (1) | NO20061325L (es) |
| RU (1) | RU2006112834A (es) |
| TW (1) | TW200518752A (es) |
| WO (1) | WO2005027842A2 (es) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6569853B1 (en) * | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
| US20050100508A1 (en) * | 2003-11-12 | 2005-05-12 | Nichols M. J. | Methods for identifying drug combinations for the treatment of proliferative diseases |
| US20050158320A1 (en) * | 2003-11-12 | 2005-07-21 | Nichols M. J. | Combinations for the treatment of proliferative diseases |
| US20050154455A1 (en) * | 2003-12-18 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
| WO2006039721A2 (en) | 2004-10-08 | 2006-04-13 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
| US8012949B2 (en) | 2004-10-08 | 2011-09-06 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS |
| TW200716141A (en) * | 2005-05-05 | 2007-05-01 | Combinatorx Inc | Compositions and methods for treatment for neoplasms |
| EP1996211A4 (en) * | 2006-03-09 | 2010-03-17 | Lawrence Richard Bernstein | GALLIUM COMPOSITIONS FOR THE TREATMENT OF LIVER CANCER AND METHODS OF USE |
| JP2009530414A (ja) | 2006-03-17 | 2009-08-27 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ | ビスホスホネート化合物及び方法 |
| JP5113038B2 (ja) * | 2006-03-23 | 2013-01-09 | テムリック株式会社 | 癌治療用キットおよび癌治療用医薬組成物 |
| CA2650520A1 (en) | 2006-04-24 | 2008-01-31 | Gloucester Pharmaceuticals | Treatment of ras-expressing tumors |
| WO2007146730A2 (en) | 2006-06-08 | 2007-12-21 | Gloucester Pharmaceuticals | Deacetylase inhibitor therapy |
| US9539241B2 (en) | 2006-07-12 | 2017-01-10 | Mobius Therapeutics, Llc | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
| US9205075B2 (en) | 2006-07-12 | 2015-12-08 | Mobius Therapeutics, Llc | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
| US7806265B2 (en) * | 2006-07-12 | 2010-10-05 | Mobius Therapeutics, Llc | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
| US20080241274A1 (en) * | 2006-11-28 | 2008-10-02 | Ziopharm Oncology, Inc. | Indibulin therapy |
| AU2007342028B2 (en) | 2006-12-29 | 2013-06-13 | Celgene Corporation | Purifiction of romidepsin |
| US20120082659A1 (en) * | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
| US8212010B2 (en) * | 2008-02-25 | 2012-07-03 | Expression Drug Designs, Llc | Sphingosine 1-phosphate antagonism |
| JP5537000B2 (ja) | 2008-08-13 | 2014-07-02 | 富士通株式会社 | マルチメディア放送・同報サービス通信制御方法及び装置 |
| WO2010086964A1 (ja) * | 2009-01-28 | 2010-08-05 | 株式会社 静岡カフェイン工業所 | がん治療のための併用療法 |
| MX347225B (es) | 2010-06-04 | 2017-04-19 | Abraxis Bioscience Llc * | Metodos de tratamiento contra el cancer pancreatico. |
| MX342913B (es) | 2010-07-12 | 2016-10-19 | Celgene Corp * | Formas solidas de romidepsina y sus usos. |
| US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
| WO2012079075A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Deuterated phthalimide derivatives |
| US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
| WO2012096654A1 (en) * | 2011-01-11 | 2012-07-19 | Mount Sinai School Of Medicine | Methods and compositions for treating cancer and related methods |
| US9314473B2 (en) | 2011-02-03 | 2016-04-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
| JP2014509323A (ja) * | 2011-02-28 | 2014-04-17 | マックマスター ユニヴァーシティ | ドーパミン受容体遮断薬による癌の処置 |
| CN102274238B (zh) * | 2011-06-30 | 2012-10-03 | 山东弘立医学动物实验研究有限公司 | 一种治疗胰腺癌的药物组合物 |
| US9187439B2 (en) | 2011-09-21 | 2015-11-17 | Inception Orion, Inc. | Tricyclic compounds useful as neurogenic and neuroprotective agents |
| EP2771014A4 (en) * | 2011-10-28 | 2015-07-08 | Univ Nat Yang Ming | PHARMACEUTICAL COMPOSITION FOR ELIMINATING CANCER STEM CELLS |
| WO2013130849A1 (en) | 2012-02-29 | 2013-09-06 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| US8809299B2 (en) | 2012-03-28 | 2014-08-19 | Mcmaster University | Combination therapy for the treatment of cancer |
| US9249093B2 (en) | 2012-04-20 | 2016-02-02 | Concert Pharmaceuticals, Inc. | Deuterated rigosertib |
| AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
| JP2015534989A (ja) | 2012-10-22 | 2015-12-07 | コンサート ファーマシューティカルズ インコーポレイテッド | ｛ｓ−３−（４−アミノ−１−オキソ−イソインドリン−２−イル）（ピペリジン−３，４，４，５，５−ｄ５）−２，６−ジオン｝の固体形態 |
| JP6348115B2 (ja) | 2012-10-26 | 2018-06-27 | ザ ユニバーシティー オブ クイーンズランド | がん療法のためのエンドサイトーシス阻害剤および抗体の使用 |
| AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
| WO2014110322A2 (en) | 2013-01-11 | 2014-07-17 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| WO2015080681A1 (en) * | 2013-11-29 | 2015-06-04 | Andac Ahmet Cenk | Phenothiazine-pyrimidine-2,4(1 h, 3h)-dione compounds for the treatment of cancer |
| NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
| US10940150B2 (en) | 2014-07-28 | 2021-03-09 | Technische Universitaet Dresden | Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27 |
| WO2016036676A1 (en) * | 2014-09-02 | 2016-03-10 | Jane Hsiao | Pharmaceutical composition for treatment of cancer using phenothiazine |
| US20170304388A1 (en) * | 2014-10-24 | 2017-10-26 | Launx Biomedical Co., Ltd. | New indication of cardiovascular drugs for preparation of cancer inhibition pharmaceutical composition |
| WO2017000084A1 (zh) * | 2015-06-30 | 2017-01-05 | 上海交通大学 | Promethazine在制备抗肝癌和/或结肠癌和/或肺癌产品中的应用 |
| WO2017180086A1 (en) * | 2016-04-11 | 2017-10-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
| SG11201806515RA (en) | 2016-03-02 | 2018-09-27 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
| US11229703B2 (en) * | 2016-04-06 | 2022-01-25 | Noxopharm Limited | Radiotherapy improvements |
| JP2019513828A (ja) | 2016-04-06 | 2019-05-30 | ノクソファーム リミティド | 改善された薬物動態を有するイソフラボノイド組成物 |
| KR102005887B1 (ko) * | 2016-12-09 | 2019-07-31 | 서울대학교산학협력단 | 뇌종양의 예방 또는 치료용 약학 조성물 |
| JP2023519990A (ja) | 2020-03-30 | 2023-05-15 | ノクソファーム リミティド | 感染に関連する炎症の治療のための方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2645640A (en) * | 1953-07-14 | Phenthiazine derivatives | ||
| US5104858A (en) * | 1988-09-29 | 1992-04-14 | Yale University | Sensitizing multidrug resistant cells to antitumor agents |
| US6569853B1 (en) * | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
| US6642221B1 (en) * | 2000-11-15 | 2003-11-04 | Parker Hughes Institute | Vanadium compounds as anti-proliferative agents |
| US6992082B2 (en) * | 2001-01-19 | 2006-01-31 | Cytokinetics, Inc. | Phenothiazine kinesin inhibitors |
| CA2492059A1 (en) * | 2002-07-11 | 2004-01-22 | Combinatorx, Incorporated | Combinations of drugs for the treatment of neoplasms |
| US20050054708A1 (en) * | 2003-07-28 | 2005-03-10 | Nichols Matthew James | Combinations of drugs for the treatment of neoplasms |
| AR047938A1 (es) * | 2003-08-25 | 2006-03-15 | Combinatorx Inc | Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas |
-
2004
- 2004-09-16 JP JP2006527024A patent/JP2007505914A/ja not_active Withdrawn
- 2004-09-16 BR BRPI0414568-2A patent/BRPI0414568A/pt not_active IP Right Cessation
- 2004-09-16 KR KR1020067007244A patent/KR20070012618A/ko not_active Withdrawn
- 2004-09-16 CA CA002538570A patent/CA2538570A1/en not_active Abandoned
- 2004-09-16 RU RU2006112834/04A patent/RU2006112834A/ru not_active Application Discontinuation
- 2004-09-16 MX MXPA06003066A patent/MXPA06003066A/es not_active Application Discontinuation
- 2004-09-16 CN CNA2004800332942A patent/CN1878556A/zh active Pending
- 2004-09-16 EP EP04788798A patent/EP1670477A2/en not_active Withdrawn
- 2004-09-16 WO PCT/US2004/030368 patent/WO2005027842A2/en not_active Ceased
- 2004-09-16 AU AU2004273910A patent/AU2004273910A1/en not_active Abandoned
- 2004-09-17 US US10/944,574 patent/US20050137185A1/en not_active Abandoned
- 2004-09-17 TW TW093128192A patent/TW200518752A/zh unknown
- 2004-09-20 AR ARP040103378A patent/AR046163A1/es unknown
-
2006
- 2006-03-09 IL IL174232A patent/IL174232A0/en unknown
- 2006-03-23 NO NO20061325A patent/NO20061325L/no not_active Application Discontinuation
- 2006-04-05 IS IS8398A patent/IS8398A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005027842A3 (en) | 2005-12-22 |
| RU2006112834A (ru) | 2007-10-27 |
| US20050137185A1 (en) | 2005-06-23 |
| IL174232A0 (en) | 2006-08-01 |
| IS8398A (is) | 2006-04-05 |
| EP1670477A2 (en) | 2006-06-21 |
| BRPI0414568A (pt) | 2006-11-07 |
| WO2005027842A2 (en) | 2005-03-31 |
| WO2005027842A8 (en) | 2006-05-18 |
| MXPA06003066A (es) | 2006-06-20 |
| CA2538570A1 (en) | 2005-03-31 |
| TW200518752A (en) | 2005-06-16 |
| JP2007505914A (ja) | 2007-03-15 |
| NO20061325L (no) | 2006-06-06 |
| CN1878556A (zh) | 2006-12-13 |
| KR20070012618A (ko) | 2007-01-26 |
| AU2004273910A1 (en) | 2005-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR046163A1 (es) | Combinaciones de farmacos para el tratamiento de neoplasmas | |
| EA202090932A1 (ru) | Способы введения некоторых vmat2-ингибиторов | |
| EA201991780A1 (ru) | Способы введения некоторых vmat2-ингибиторов | |
| AR049985A1 (es) | Tratamiento de combinacion para enfermedades malignas no hematologicas | |
| ECSP066383A (es) | Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias | |
| CY1112200T1 (el) | Συνδυασμοι για τη θεραπεια ασθενειων που ενεχουν κυτταρικο πολλαπλασιασμο | |
| CO6220933A2 (es) | Formulaciones de dosis unitaria y metdods para el tratamiento de la trombosis con un inhibidor oral del facror xa | |
| UY31068A1 (es) | Ligandos purinoreceptores p2x, metodos para la prparacion de los mismos, composiciones farmaceuticas que los contienen y sus usos 570 | |
| IS8503A (is) | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| AR045040A1 (es) | Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos | |
| PH12023550160A1 (en) | Combinations for the Treatment of Cancer | |
| WO2022261240A3 (en) | Dimethoxyphenylalkylamine activators of serotonin receptors | |
| CL2022000458A1 (es) | Ciertos compuestos de pladienolida y métodos de uso. (divisional de solicitud 202002604) | |
| BRPI0507824A (pt) | hidroxiapatita, processo para a preparação de um particulado de hidroxiapatita marcada com radionuclìdeo, composição farmacêutica, uso de hidroxiapatita e de um radionuclìdeo emissor de alfa ou um radionuclìdeo emissor de beta, dispositivo, e, método de tratamento radioquìmico de um ser humano ou de um indivìduo animal não humano necessitando do mesmo | |
| AR043444A1 (es) | Profarmacos de diaril-2- 5h -furanonas que liberan oxido nitrico como inhibidores de la ciclooxigenasa-2 | |
| RU2010151660A (ru) | Способы лечения множественной миеломы | |
| CO2022005999A2 (es) | Inhibidores del factor d del complemento para administración oral | |
| BR112022018020A2 (pt) | Formas cristalinas de um composto farmacêutico | |
| IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
| MX2024009444A (es) | Métodos de tratamiento para la fibrosis quística | |
| ATE536178T1 (de) | Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis | |
| AR013462A1 (es) | Nuevos peptidomimeticos para el tratamiento de trastornos oseos, metodos para su produccion y drogas que contienen estos compuestos | |
| PE20231945A1 (es) | Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados | |
| AR048021A1 (es) | Derivados nucleosido fosfonato utiles en el tratamiento de infecciones de hiv. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |